My first university degree, a master degree of science, was in genetics and immunology from the university of Rouen, in France. In this context, I performed several internships on applying oral tolerization protocols in the context of gene therapy which led to my first participation in a scientific publication.
Being deeply passionate about computer science since my childhood, I decided to get a look at the bio-informatic field because it perfectly combines my two main area of interest: biology and computer science. For this purpose, I completed two other master’s degree, a first one in computer science, delivered by Aix-Marseille University, during which I had a deeper and broad teaching with strong basis in algorithmic along with the best practises in the computer science industry. This degree gave me the right bases to complete a second master’s degree in in silico drug discovery, delivered by Paris Diderot University during which I had a very rich internship at Sanofi and a first insight of the pharmaceutical industry with the most used molecular modelling techniques.
I then worked at Inria during two years before co-founding OneAngstrom, a start-up commercializing the SAMSON software platform. During that time, I integrated to the SAMSON platform many well-known and widely used molecular modelling tools like GROMACS, RDKit or Hex as well as academic tools which were only used by few persons in order to make them more accessible to more persons around the world. Thanks to that experience in integrating different technological blocks, I joined Qubit Pharmaceuticals, in order to take on the challenge of creating the world first drug discovery platform running on quantum computers and based on several cutting-edge and independent blocks. At Qubit Pharmaceuticals, I am working on the Atlas platform by integrating scientifically validated technological bricks and making them communicate in the most efficient way to get the best out of them.